Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of SP2086 and Metformin
NCT02813863Phase 1Completed
- Sponsor
- Hengrui
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of retagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax) of SP2086 at Day 9, Area Under the Plasma Concentration-Time Curve (AUC) of SP2086 at Day 9 and 4 more. Started Dec 2015; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02813863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813863.